EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, LLC finds that twelve months post-launch of KRYSTEXXA, surveyed rheumatologists appear to have high awareness of KRYSTEXXA and reserve it for chronic refractory gout patients. While still listed as the number one disadvantage of KRYSTEXXA by half of respondents, concerns regarding anaphylaxis/infusion reactions have stabilized.
Twenty-nine percent of the surveyed rheumatologists report that they have initiated Savient’s KRYSTEXXA (pegloticase) in at least one patient during this fourth wave of the LaunchTrends®: KRYSTEXXA report series and are relatively satisfied with the product. This usage is up from 23 percent reported in the previous wave of the survey published six months ago. In addition, rheumatologists estimate that 17 percent of their severe gout patients are eligible candidates for KRYSTEXXA.
Rheumatologists agree that KRYSTEXXA’s main advantages are its rapid and significant decrease in serum uric acid levels, rapid tophi resolution and its unique mechanism of action. However, the main barriers to rheumatologists’ usage of KRYSTEXXA has been concerns regarding anaphylaxis or infusion reactions, followed by its dosing frequency and intravenous route of administration, i.e., an infusion every two weeks and significant out of pocket costs for the patients.
LaunchTrends®: KRYSTEXXA is a series of four post-launch syndicated reports designed to track the uptake of Savient’s KRYSTEXXA at one month, three months, six months and 12 months following its commercial availability. In the current wave of research, which measures KRYSTEXXA’s market impact at twelve months post launch, BioTrends surveyed 101 rheumatologists and conducted qualitative interviews with a subset of 15 of the respondents in March 2012. This is the final report of this series. However, BioTrends will continue to track the usage of KRYSTEXXA in the on-going TreatmentTrends®: Gout U.S. report series.
About BioTrends Research Group, LLC
BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.